Non-small-cell lung cancer (NSCLC) is one of the most frequent cancer types and is
responsible for the majority of cancer-related deaths worldwide. The management of …

Importance To date, no meta-analyses have comprehensively assessed the association of
neoadjuvant chemoimmunotherapy with clinical outcomes in non–small cell lung cancer …

The treatment landscape of resectable early-stage non-small cell lung cancer (NSCLC) is
transforming due to the approval of novel adjuvant and neoadjuvant systemic treatments …

The treatment landscape of resectable early-stage non-small cell lung cancer (NSCLC) is
set to change significantly due to encouraging results from randomized trials evaluating …

Lung cancer is the second most common and the deadliest type of cancer worldwide.
Clinically, non‐small cell lung cancer (NSCLC) is the most common pathological type of …

As immunotherapy makes its way into the perioperative setting, a growing number of clinical
trials are expanding the evidence base for resectable non-small cell lung cancer (NSCLC) …

Simple Summary The benefit of neoadjuvant chemoimmunotherapy was compared with
chemotherapy for localized NSCLC in several trials. We conducted a systematic review and …

Methods: A literature search for randomized phase 2/3 trials on the treatment of early-stage
NSCLC was performed based on PubMed and the content on major oncology congresses …

Importance Randomized clinical trials (RCTs) with neoadjuvant immune checkpoint
inhibitors (ICIs) plus chemotherapy (ICI-chemotherapy) for patients with early-stage non …

The reduction in lung cancer mortality rates over the past decade can be partially ascribed to
advancements in immunotherapy. Immune checkpoint inhibitors (ICIs) have transformed the …